{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:52:00Z","timestamp":1765889520914,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thoracic.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Surgery Clinics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.thorsurg.2025.07.001","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T14:50:12Z","timestamp":1754405412000},"page":"461-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Precision Medicine in Thoracic Surgery"],"prefix":"10.1016","volume":"35","author":[{"given":"Constantine M.","family":"Poulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot L.","family":"Servais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.thorsurg.2025.07.001_bib1","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Li\u00e8vre","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.thorsurg.2025.07.001_bib3","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/JTO.0000000000000392","article-title":"Thymic tumors: adopting an orphan thoracic tumor as a model of personalized medicine","volume":"9","author":"Girard","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.07.001_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.thorsurg.2017.01.007","article-title":"Management of primary soft tissue tumors of the chest wall","volume":"27","author":"Cipriano","year":"2017","journal-title":"Thorac Surg Clin"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.07.001_bib5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejso.2016.05.031","article-title":"The effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas","volume":"43","author":"Stahl","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.07.001_bib6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jso.26275","article-title":"Impact of resection margin on outcomes in high-grade soft tissue sarcomas of the extremity-A USSC analysis","volume":"123","author":"Chouliaras","year":"2021","journal-title":"J Surg Oncol"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.07.001_bib7","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1001\/jamaoncol.2018.0723","article-title":"Targetable alterations in adult patients with soft-tissue sarcomas: insights for personalized therapy","volume":"4","author":"Lucchesi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.thorsurg.2025.07.001_bib8","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.1158\/1078-0432.CCR-18-4032","article-title":"Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations","volume":"25","author":"Suehara","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.07.001_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1158\/1078-0432.CCR-18-4212","article-title":"Genomic profiling identifies association of idh1\/idh2 mutation with longer relapse-free and metastasis-free survival in high-grade chondrosarcoma","volume":"26","author":"Zhu","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.07.001_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13073-022-01084-0","article-title":"A genetic model for central chondrosarcoma evolution correlates with patient outcome","volume":"14","author":"Cross","year":"2022","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.07.001_bib11","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1038\/s41467-022-30496-0","article-title":"Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma","volume":"13","author":"Gounder","year":"2022","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.thorsurg.2025.07.001_bib12","doi-asserted-by":"crossref","first-page":"39254","DOI":"10.18632\/oncotarget.16845","article-title":"Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas","volume":"8","author":"Groisberg","year":"2017","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.thorsurg.2025.07.001_bib13","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra2103423","article-title":"New horizons in the treatment of osteosarcoma","volume":"385","author":"Meltzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-030-43032-0_10","article-title":"Genetically modified t-cell therapy for osteosarcoma: into the roaring 2020s","volume":"1257","author":"DeRenzo","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.575737","article-title":"Combination of t-cell bispecific antibodies with pd-l1 checkpoint inhibition elicits superior anti-tumor activity","volume":"10","author":"Sam","year":"2020","journal-title":"Front Oncol"},{"issue":"23","key":"10.1016\/j.thorsurg.2025.07.001_bib16","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1158\/1078-0432.CCR-21-1893","article-title":"Fresh tissue multi-omics profiling reveals immune classification and suggests immunotherapy candidates for conventional chondrosarcoma","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.thorsurg.2025.07.001_bib17","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1158\/1078-0432.CCR-12-3647","article-title":"Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.07.001_bib18","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1038\/s41467-020-18817-7","article-title":"A system-level approach identifies HIF-2\u03b1 as a critical regulator of chondrosarcoma progression","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.thorsurg.2025.07.001_bib19","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00268-019-05132-6","article-title":"Largely unchanged annual incidence and overall survival of pleural mesothelioma in the USA","volume":"43","author":"Keshava","year":"2019","journal-title":"World J Surg"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.07.001_bib20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"issue":"13","key":"10.1016\/j.thorsurg.2025.07.001_bib21","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the treatment of malignant pleural mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.07.001_bib22","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3390\/cancers16101817","article-title":"Ki67 tumor expression predicts treatment benefit achieved by macroscopic radical lung-preserving surgery in pleural mesothelioma-a retrospective multicenter analysis","volume":"16","author":"Hintermair","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.07.001_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.07.001_bib24","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic landscape of malignant mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol Cancer Therapeut"},{"issue":"35","key":"10.1016\/j.thorsurg.2025.07.001_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of bap1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib26","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104481","article-title":"Unleashing precision: a review of targeted approaches in pleural mesothelioma","volume":"203","author":"Occhipinti","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10272","key":"10.1016\/j.thorsurg.2025.07.001_bib28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.thorsurg.2025.07.001_bib29","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (Mist1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.thorsurg.2025.07.001_bib30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (Mist2): a single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.thorsurg.2025.07.001_bib31","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.3390\/cancers14235925","article-title":"Cdk4\/6 inhibition enhances the efficacy of standard chemotherapy treatment in malignant pleural mesothelioma cells","volume":"14","author":"Terenziani","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.thorsurg.2025.07.001_bib32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamaoncol.2023.6789","article-title":"Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: the atomic-meso randomized clinical trial","volume":"10","author":"Szlosarek","year":"2024","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.thorsurg.2025.07.001_bib33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.299.6.672","article-title":"Medical treatment of advanced testicular cancer","volume":"299","author":"Feldman","year":"2008","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.07.001_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.thorsurg.2008.09.002","article-title":"Multimodality treatment of germ cell tumors of the mediastinum","volume":"19","author":"Kesler","year":"2009","journal-title":"Thorac Surg Clin"},{"issue":"7","key":"10.1016\/j.thorsurg.2025.07.001_bib35","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/JTO.0b013e31821d513e","article-title":"Resection of primary mediastinal non-seminomatous germ cell tumors: a 28-year experience at memorial sloan-kettering cancer center","volume":"6","author":"Sarkaria","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"33","key":"10.1016\/j.thorsurg.2025.07.001_bib36","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2009.26.8128","article-title":"Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy","volume":"28","author":"Lorch","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib37","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2018.36.15_suppl.4555","article-title":"Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT)","volume":"36","author":"Necchi","year":"2018","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.thorsurg.2025.07.001_bib38","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1634\/theoncologist.2018-0430","article-title":"Genomic features for therapeutic insights of chemotherapy-resistant, primary mediastinal nonseminomatous germ cell tumors and comparison with gonadal counterpart","volume":"24","author":"Necchi","year":"2019","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.thorsurg.2025.07.001_bib39","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1093\/oncolo\/oyac197","article-title":"Tp53 alterations are associated with poor survival in patients with primary mediastinal nonseminoma germ cell tumors","volume":"27","author":"Bacon","year":"2022","journal-title":"Oncologist"},{"issue":"21","key":"10.1016\/j.thorsurg.2025.07.001_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111774","article-title":"The role of tp53 in cisplatin resistance in mediastinal and testicular germ cell tumors","volume":"22","author":"Timmerman","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.thorsurg.2025.07.001_bib41","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.3390\/ijms22084263","article-title":"Targeting of deregulated wnt\/\u03b2-catenin signaling by pri-724 and lgk974 inhibitors in germ cell tumor cell lines","volume":"22","author":"Schmidtova","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"33","key":"10.1016\/j.thorsurg.2025.07.001_bib42","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2016.68.7798","article-title":"Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors","volume":"34","author":"Bagrodia","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.thorsurg.2025.07.001_bib43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.thorsurg.2025.07.001_bib44","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0959-8049(96)00517-5","article-title":"Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours","volume":"33","author":"Hartmann","year":"1997","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.07.001_bib45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.thorsurg.2025.07.001_bib46","doi-asserted-by":"crossref","first-page":"558-e1098","DOI":"10.1002\/onco.13682","article-title":"Pembrolizumab in patients with advanced metastatic germ cell tumors","volume":"26","author":"Tsimberidou","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib47","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1200\/JCO.2018.36.15_suppl.4547","article-title":"Apache: an open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): results at the end of first stage","volume":"36","author":"Raggi","year":"2018","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.thorsurg.2025.07.001_bib48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1634\/theoncologist.2017-0544","article-title":"Treatment of cd30-expressing germ cell tumors and sex cord stromal tumors with brentuximab vedotin: identification and report of seven cases","volume":"23","author":"Albany","year":"2018","journal-title":"Oncologist"},{"issue":"28","key":"10.1016\/j.thorsurg.2025.07.001_bib49","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.23.01960","article-title":"Personalized chemotherapy on the basis of tumor marker decline in poor-prognosis germ-cell tumors: updated analysis of the getug-13 phase iii trial","volume":"42","author":"Fizazi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1118610","article-title":"Immune checkpoint inhibitors and chimeric antigen receptor (Car)-t cell therapy: potential treatment options against testicular germ cell tumors","volume":"14","author":"Schepisi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib51","article-title":"Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999-2019","volume":"13","author":"Gerber","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.07.001_bib52","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 who classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.07.001_bib53","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.thorsurg.2025.07.001_bib54","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3390\/cancers14143388","article-title":"Targeted next-generation sequencing of thymic epithelial tumours revealed pathogenic variants in kit, erbb2, kras, and tp53 in 30% of thymic carcinomas","volume":"14","author":"Szpechcinski","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.thorsurg.2025.07.001_bib55","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/oncolo\/oyac115","article-title":"Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers","volume":"27","author":"Girard","year":"2022","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.thorsurg.2025.07.001_bib56","doi-asserted-by":"crossref","first-page":"7536","DOI":"10.21037\/jtd.2019.12.52","article-title":"Genomic alterations in thymoma-molecular pathogenesis?","volume":"12","author":"Oberndorfer","year":"2020","journal-title":"J Thorac Dis"},{"issue":"2","key":"10.1016\/j.thorsurg.2025.07.001_bib57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/JTO.0000000000000397","article-title":"Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis","volume":"10","author":"Moreira","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.thorsurg.2025.07.001_bib58","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (Tets)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.thorsurg.2025.07.001_bib60","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","article-title":"Pi3k as a potential therapeutic target in thymic epithelial tumors","volume":"11","author":"Alberobello","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2020.04.036","article-title":"Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma","volume":"145","author":"Arjonen","year":"2020","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.thorsurg.2025.07.001_bib62","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/ejcts\/ezv288","article-title":"Surgical treatment of thymoma: an 11-year experience with 761 patients","volume":"49","author":"Zhao","year":"2016","journal-title":"Eur J Cardio Thorac Surg"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib63","article-title":"Induction strategy for locally advanced thymoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.thorsurg.2025.07.001_bib64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.thorsurg.2025.07.001_bib65","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase ii trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.thorsurg.2025.07.001_bib66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (Pd-l1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.thorsurg.2025.07.001_bib67","doi-asserted-by":"crossref","first-page":"e20647","DOI":"10.1200\/JCO.2023.41.16_suppl.e20647","article-title":"Preliminary efficacy, safety, and immunomodulatory effects of PT-112 from a phase 2 proof of concept study in patients (pts) with thymic epithelial tumors (TETs)","volume":"41","author":"McAdams","year":"2023","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.thorsurg.2025.07.001_bib68","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/13543784.2022.2113373","article-title":"Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials","volume":"31","author":"Conforti","year":"2022","journal-title":"Expet Opin Invest Drugs"}],"container-title":["Thoracic Surgery Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154741272500043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154741272500043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T21:44:29Z","timestamp":1761774269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154741272500043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S154741272500043X"],"URL":"https:\/\/doi.org\/10.1016\/j.thorsurg.2025.07.001","relation":{},"ISSN":["1547-4127"],"issn-type":[{"type":"print","value":"1547-4127"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Medicine in Thoracic Surgery","name":"articletitle","label":"Article Title"},{"value":"Thoracic Surgery Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thorsurg.2025.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}